


Express Mail Label No.: EV 460337391 US  
Date of Deposit: March 27, 2006

Attorney Docket No.: 26448-510



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Egan et al.

SERIAL NUMBER : 09/905,188

EXAMINER : Cybille Delacroix-Muirheid

FILING DATE : July 13, 2001

ART UNIT : 1614

FOR : METHOD FOR TREATING FIBROTIC DISEASES OR OTHER  
INDICATIONS IC

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1page), in duplicate;
3. Copies of Cited References: B3; C2-8; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26448-510. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to


Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Customer No. 30623

Date: March 27, 2006



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Egan et al.

SERIAL NUMBER : 09/905,188

EXAMINER : Cybille Delacroix-Muirheid

FILING DATE : July 13, 2001

ART UNIT : 1614

FOR : METHOD FOR TREATING FIBROTIC DISEASES OR OTHER  
INDICATIONS IC

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report for EP 01 95 8946, mailed February 8, 2006 in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

✓  
APPLICANTS: Egan, et al.  
U.S.S.N.: 09/905,188

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26448-510.

Respectfully submitted,

 50,572

Ivor R. Elrifi, Reg. No. 39,529

Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

Address all written correspondence to

**Customer no.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: March 27, 2006

TRA 2135414v.1



Please type a plus sign (+) in this box



<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/905,188
	<b>Filing Date</b>	07/13/2001
	<b>First Named Inventor</b>	Egan
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Cybillie Delacroix-Muirheid
	<b>Attorney Docket Number</b>	26448-510

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B3	WO	96/22095	ALTEON INC.; THE PICOWER INSTITUTE FOR MEDICAL RESEARCH	07/25/96		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C2	Asif et al. <i>PNAS</i> , 97(6):2809-2813 (2000)
	C3	Lee et al. <i>J. Am. Soc. Nephrol.</i> , Abstract only, 9:641A (1997)
	C4	Rosser et al. <i>Diabetes Metab.</i> , 26(4):16-24 (2000)
	C5	Sakata et al. <i>J. Atheroscler. Thromb.</i> , 7(3):169-176 (2000)
	C6	Twigg et al. <i>Endocrinol.</i> , 142(5):1760-1769 (2001)
	C7	Wolffenbuttel et al. <i>Proc. Natl. Acad. Sci. USA</i> , 95(8):4630-4634 (1998)
	C8	Supplementary European Search Report for EP 01 95 8946, mailed February 8, 2006.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.